Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Jefferies reiterates Ardelyx stock rating on contracting strategy

Jefferies reiterates Ardelyx stock rating on contracting strategy

Jefferies has reaffirmed a Buy rating and $8.00 price target on Ardelyx, Inc (NASDAQ:ARDX), indicating potential upside from the current stock price of $3.12. The investment firm highlighted that Ardelyx plans to adopt a cautious approach to Ibsrela contracting in 2027, aiming to allay investor concerns regarding the gross-to-net ratio.

Jefferies anticipates conservative 2027 guidance from the company, coupled with Phase III CIC topline expected in the second half of 2027. Ardelyx's stock has declined by 50% year-to-date, and 51% over the past six months. According to InvestingPro analysis, the stock appears fairly valued at its current level. Investors can access a detailed Pro Research Report on ARDX for additional insights.

In a separate development, Ardelyx reported a 19% increase in third-quarter revenue compared to the same period last year, though it fell short of analysts' forecasted $129.22 million, with product revenue reaching $125.5 million. Despite this, net loss narrowed to $700,000, signaling progress towards profitability. Investors seem to be optimistic about the strong demand for Ardelyx's product IBSRELA and the company's reaffirmed full-year guidance, leading to positive market response and growing financial leverage for the biotech firm.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Finance & Markets

More from Tuesday 17 November →